Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Extended follow-up of AMBASSADOR: adjuvant pembrolizumab in MIUC

Andrea Apolo • 13 Sep 2024
ESMO 2024
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Pembrolizumab
AMBASSADOR

Andrea Apolo, MD, National Cancer Institute, Bethesda, MD, comments on the extended follow-up disease-free survival (DFS) results from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in patients with muscle-invasive and locally advanced urothelial carcinoma (MIUC) of the bladder. Pembrolizumab was found to continue to be superior in terms of DFS. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrea Apolo

Subset analysis of pembrolizumab efficacy in the AMBASSADOR study
2:00
Subset analysis of pembrolizumab efficacy in the AMBASSADOR study
Andrea Apolo • 13 Sep 2024
Biomarkers for muscle-invasive bladder cancer in the AMBASSADOR trial
0:57
Biomarkers for muscle-invasive bladder cancer in the AMBASSADOR trial
Andrea Apolo • 25 Jan 2024
Assessing the role of perioperative immunotherapy in MIBC
0:54
Assessing the role of perioperative immunotherapy in MIBC
Andrea Apolo • 25 Jan 2024
AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
2:59
AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
Andrea Apolo • 25 Jan 2024

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals